Acertis Patent-Cliff Exposure & CMS Drug Spending Portfolio
Acertis (US): 3 reconciled FDA prescription therapies, $1.4M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $1.4M |
| 2024 Medicare Part D Spend | $1.0M |
| 2024 Medicaid Spend | $325K |
| California HCAI SB 17 Filings | 4 WAC filings (max 43.8% 2-yr change) |